Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amrubicin in metastatic breast cancer
NCT00380835Phase 2Withdrawn
- Sponsor
- Celgene Corporation
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of amrubicin in breast cancer, sponsored by Celgene Corporation. Status: withdrawn.
02
Drugs
amrubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00380835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00380835.